Special Issue "Pharmacology and Bioinformatics and Applications in Inflammation and Cancer"

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Omics/Informatics".

Deadline for manuscript submissions: 31 December 2023 | Viewed by 208

Special Issue Editors

Institute for TCM-X, MOE Key Laboratory of Bioinformatics, Bioinformatics Division, BNRist, Department of Automation, Tsinghua University, Beijing 100084, China
Interests: network pharmacology; systems biology; inflammation; cancer
Department of Molecular Pharmacology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin 300060, China
Interests: molecular pharmacology; network pharmacology; cancer; bioinformatics
Department of Biotechnology and Pharmaceutical Science, School of Life Sciences, Nanjing University, Nanjing, China
Interests: nonresolving inflammation; inflammatory diseases; inflammation-related cancer; drug target; small-molecule compound

Special Issue Information

Dear Colleagues,

Inflammation is causally related to cancer development through processes of complex biomolecular changes. A better understanding of the molecular mechanisms underlying inflammation-induced cancer may prospectively facilitate the discovery of drugs targeting cancer initiation or progression. Over the past decade, the development of high-throughput omics approaches and novel bioinformatics tools has paved the way for clarifying the mechanisms underlying these processes. Meanwhile, with the recent advances in systems biology and bioinformatics, network pharmacology has emerged and significantly reshaped the paradigm of drug discovery.

In this Special Issue, we invite researchers to submit work presenting the most recent advances in and future perspectives on the key molecular events which determine the inflammation-to-cancer transformation and may serve as the therapeutic targets or the screening/diagnostic biomarkers. Equally welcome are the applications of innovative in silico or experimental approaches to the development of potential therapeutics for inflammation-induced cancer. Additionally, due to biomolecular complexity and the fact that several biomedical fields are involved, studies using multi- and interdisciplinary approaches to elucidate the drug action and molecular mechanisms underlying inflammation-to-cancer phenotypes are especially welcome.

Prof. Dr. Shao Li
Prof. Dr. Liren Liu
Prof. Dr. Yang Sun
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • inflammation-induced cancer
  • bioinformatics
  • network pharmacology
  • systems biology
  • therapeutic target
  • diagnostic biomarker
  • molecular mechanism
  • drug action
  • drug discovery
  • cancer therapy
  • Chinese herbal compounds

Published Papers

This special issue is now open for submission.
Back to TopTop